Market Place
Sourcing Support
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
11 Jul 2024 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
16 Apr 2024 //
GLOBENEWSWIRE
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement
13 Mar 2024 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering
19 Sep 2023 //
GLOBENEWSWIRE
Eloxx Reports Positive Results in All Patients Treated with ELX-02
18 Sep 2023 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
07 Sep 2023 //
GLOBENEWSWIRE
Eloxx Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Study
14 Aug 2023 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance
03 Aug 2023 //
GLOBENEWSWIRE
Eloxx Announces Publication Demonstrating the Power of TURBO-ZM Platform
10 Jul 2023 //
GLOBENEWSWIRE
Eloxx Key Opinion Leader Event Highlights Unmet Need of Alport Syndrome
28 Jun 2023 //
GLOBENEWSWIRE
Eloxx Pharma Highlights Recent Alport Syndrome Natural History Data
21 Jun 2023 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome
21 Jun 2023 //
GLOBENEWSWIRE
Eloxx repackages ELX-02 data in cystic fibrosis as it eyes pivotal trial
15 Jun 2023 //
PHARMACEUTICAL TECHNOLOGY
Eloxx Announces Data Assessment from Phase 2 Combination Trial of ELX-02
14 Jun 2023 //
GLOBENEWSWIRE
Eloxx Granted Extension by Nasdaq to Regain Compliance
06 Jun 2023 //
GLOBENEWSWIRE
Eloxx aims to take lead candidate into PhIII for rare disease
24 May 2023 //
ENDPTS
Eloxx Pharma Intends to Advance ELX-02 into Pivotal Trial for the Treatment
24 May 2023 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Reports 1Q 2023 FYR and Operating Results
15 May 2023 //
GLOBENEWSWIRE
Eloxx Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
02 May 2023 //
GLOBENEWSWIRE
Eloxx Reports Fourth Quarter 2022 Financial Results
03 Apr 2023 //
GLOBENEWSWIRE
Eloxx Announces Submission of IND Application for ZKN-013
28 Mar 2023 //
GLOBENEWSWIRE
Eloxx Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
06 Mar 2023 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals begins subject dosing in Alport syndrome therapy trial
28 Feb 2023 //
CLINICAL TRIALS ARENA
Eloxx Pharma Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02
27 Feb 2023 //
GLOBENEWSWIRE
Eloxx Announces First Patients Enrolled in PII Study Evaluating ELX-02
25 Jan 2023 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective
01 Dec 2022 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Reports 3Q 2022 Financial and Operating Results
10 Nov 2022 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Announces Opening of Trial Sites for Pha2 of ELX-02
01 Nov 2022 //
GLOBENEWSWIRE
In Cystic Fibrosis Failure, Eloxx Sees Silver Lining for Alport Syndrome
16 Sep 2022 //
BIOSPACE
Eloxx Pharma Reports Topline Results from PII Combination Trial of ELX-02
15 Sep 2022 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Announces Changes to Board of Directors
05 Jul 2022 //
GLOBENEWSWIRE
Eloxx Pharma Reports First Quarter 2022 Financial and Operating Results
10 May 2022 //
GLOBENEWSWIRE
Eloxx Pharma Reports Fourth Quarter 2021 Financial and Operating Results
31 Mar 2022 //
GLOBENEWSWIRE
Eloxx Pharma Shows New Development Program for ELX-02 in Alport Syndrome
30 Mar 2022 //
GLOBENEWSWIRE
Eloxx Pharma Announces Therapeutic Development Award from CF Foundation
29 Mar 2022 //
GLOBENEWSWIRE
Eloxx Shares Slump As Phase 2 Cystic Fibrosis Data Fails To Cheer Investors
18 Nov 2021 //
YAHOOFINANCE
Eloxx Reports +VE Topline Results from Monotherapy Portion of Phase 2 Trial
17 Nov 2021 //
TRIALSITENEWS
Eloxx Reports +ve Topline Results from Monotherapy Arms of Ph2 Trial of ELX-02
17 Nov 2021 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 M
05 Oct 2021 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals 15% Higher After FDA Fast Track Designation
09 Sep 2021 //
MARKERWATCH
Eloxx Pharmaceuticals Appoints Chief Medical Officer
08 Sep 2021 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial Results
16 Aug 2021 //
GLOBENEWSWIRE
Eloxx Pharma Provides Enrollment Update for Ongoing Phase 2 Clinical Studies
06 Jul 2021 //
GLOBENEWSWIRE
Eloxx Announces Funding Award from Cystic Fibrosis Foundation
27 May 2021 //
GLOBENEWSWIRE
Eloxx Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies
29 Apr 2021 //
GLOBENEWSWIRE
Eloxx Acquires Zikani with Hopes to Rule the RNA Wave for Rare Disease
02 Apr 2021 //
BIOSPACE
Eloxx nabs early-stage biotech Zikani Therapeutics, replaces CEO
01 Apr 2021 //
FIERCEBIOTECH
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
01 Apr 2021 //
BIOSPACE
Eloxx Acquires Zikani with Hopes to Rule the RNA Wave for Rare Disease
01 Apr 2021 //
BIOSPACE
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal
26 Jan 2021 //
GLOBENEWSWIRE
Eloxx Announces Publication of Scientific Manuscript on ELX-02
20 Jan 2021 //
GLOBENEWSWIRE
Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation)
13 Jan 2021 //
GLOBENEWSWIRE
Eloxx Presents Two Preclinical Posters the 2020 North American Cystic Fibrosis
23 Oct 2020 //
GLOBENEWSWIRE
Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals
14 Sep 2020 //
GLOBENEWSWIRE
Eloxx Announces Two Preclinical Abstracts Accepted for at the 2020 North
26 Aug 2020 //
GLOBENEWSWIRE
Enrollment in U.S. Ph2 Trial in Cystic Fibrosis Has Resumed After Being Paused
12 Aug 2020 //
GLOBENEWSWIRE
